WO1997040844A2 - Anti-hiv activity of medicinal plant extract preparation - Google Patents
Anti-hiv activity of medicinal plant extract preparation Download PDFInfo
- Publication number
- WO1997040844A2 WO1997040844A2 PCT/HU1997/000015 HU9700015W WO9740844A2 WO 1997040844 A2 WO1997040844 A2 WO 1997040844A2 HU 9700015 W HU9700015 W HU 9700015W WO 9740844 A2 WO9740844 A2 WO 9740844A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- extract
- alcoholic
- dry material
- deoxy
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000036436 anti-hiv Effects 0.000 title claims abstract description 14
- 239000000419 plant extract Substances 0.000 title claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 22
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 241001233914 Chelidonium majus Species 0.000 claims abstract description 20
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000012675 alcoholic extract Substances 0.000 claims abstract description 13
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 12
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims abstract description 11
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000006286 aqueous extract Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 229940084560 sanguinarine Drugs 0.000 claims abstract description 11
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 230000002424 anti-apoptotic effect Effects 0.000 claims abstract description 4
- 239000000654 additive Substances 0.000 claims abstract description 3
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 11
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VINIVXVRXVXNTR-UHFFFAOYSA-N Chelidonin Natural products CN1Cc2c3OCOc3ccc2C4C(O)Cc5c6OCOc6ccc5C14 VINIVXVRXVXNTR-UHFFFAOYSA-N 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940068560 greater celandine Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003579 thiophosphoric acid derivatives Chemical class 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
Definitions
- the subject of the invention are medicinal plant extract preparation and its 5 compounds with therapeutic and curative anti-HIV and anti-apoptotic effects.
- the Chelidonium majus, greater celandine is a well known herb, containing alkaloids, like chelidonine, chelerythrine, sanguinarine, protopine and also malic acid, citric acid, various salts and natural resins. The whole plant or the roots can be used as drug.
- the alcoholic tincture or aqueous extract prepared from the plant is utilized as therapeutic agent for a long time.
- the subject of the invention are medicinal plant based preparation and its compounds with therapeutic and curative anti-HIV and anti-apoptotic effects.
- the preparations of this invention are characterized is by the followings: an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and any other compounds with known anti-HIV activity, preferably 2'-deoxy-3'-azidothimidine, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonine and/or chelerythrine and/or- sanguinarine or a mixture of these compounds with 2'-deoxy- -3'-azidothimidine- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2
- the extract is prepared from the whole plant, or expediently from roots.
- the diluted solution, which is formed on extraction, is evaporated, or if required in some cases, lyophilized.
- the chelidonin, chelerythrine and sanguinarine may be isolated from the extract with preparative HPLC.
- the effects of the products and compounds prepared according to the invention, and the mode of the preparation are shown in the following examples.
- the dirt was removed from freshly picked roots of Chelidonium majus by washing and then dried partially at room temperature for 1-2 hours.
- the roots were cut up to small pieces and 100 part (mass) cut root was mixed with 250 part (mass) of 96% alcohol.
- the mixture was kept at room temperature in dark for 9 days and mixed up twice daily.
- the solid was separated from the liquid, Extract I, containing 1,5% (w/w) dry material. This product was partially evaporated at 45°C in vacuum, then the residue was mixed with two parts (mass) of alcohol.
- the mixture was filtrated.
- the filtrate contains 6,2% (w/w) dry material,Extract II.
- Example 3 The procedure was completed according to the Example N°. 1 but instead of the roots of Chelidonium majus the whole plant was utilized.
- the dry material content of Extract I was 1,89% (w/w), the Extract II contained 6,5% by weight of dry material.
- Example 3 The dry material content of Extract I was 1,89% (w/w), the Extract II contained 6,5% by weight of dry material.
- Extract 1 and Extract II were evaporated in vacuum and the dry residue dissolved in DMSO in a final concentration of 100 mg/ml. These stock solutions were diluted with RPMI to get a final drug concentration of 100 ⁇ g/ml, and used in the treatment of infected cells. H9 cells were infected with HIV, and used in this study.
- the drug solutions were added to the tissue culture (10 ⁇ cells/ml) at 1 or 6 hours prior infection, at the viral infection (0 time), 24 and 48 hours after infection.
- the final drug concentration was 10 ⁇ g/ml at each addition.
- the viruses were HIV-1 IIIB, produced by H9 cells (2xl0 5 IU/ml). The infection was completed in 2 hours at 37 °C, in CO2 incubator. When the infection of the cells was finished the cells were washed thoroughly with PBS the 0,5 million cells were seeded into 24-well plates and 2 ml medium was added into each well. The culturing was performed in CO2 incubator. The infected cell cultures were treated with Extract I and Extract II as mentioned above, appropriate control tissue cultures were also run, without drug.
- Experiment A the extract is replaced with 1 ⁇ g/ml AZT; in Experiment B: 1 ⁇ l/ml AZT 1 ⁇ g/ml dry- material of extract II is combined.
- the active compound and mixture is given to the tissue culture only once, after the viral infection.
- the concentration of produced virions were determined on the 13th day of postinfection measuring the activity of reverse transcriptase in the cell free medium.
- the reverse transcriptase activity was 19,9% compared to the control, in Experiment B this value was only 1,4%, representing 98,6% inhibition.
- MT4 cells were infected with HIV-1 IIIB and the virus replication was inhibited using the following agents: chelidonine (I), chelerythrine (III), sanguinarine (II). The inhibition of virus replication was followed by determining the reverse transcriptase activity as above, on 5th and 8th day after viral infections.
- control values were on 5th day: 153 824 cpm on 8th day: 56 266 cpm.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to medicinal plant extract preparation and its compounds with therapeutic and curative anti-HIV and anti-apoptotic effects. The medicinal plant extract preparation is: an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material, or an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and any other compounds with known anti-HIV activity, preferably 2'-deoxy-3'azidothimidine, or chelidonoine and/or chelerythrine and/or sanguinarine or a mixture of these compounds with 2'-deoxy-3'-azidothimidine, or an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2'-deoxy-3'-azidothimidine, or the above preparations and/or compounds further supplemented with known medicinal auxiliary and additive materials.
Description
ANTI-HIV ACTIVITY OF MEDICAL PLANT EXTRACT PREPARATION AND ITS COMPOUNDS WITH THERAPEUTIC AND CURATIVE EFFECT
The subject of the invention are medicinal plant extract preparation and its 5 compounds with therapeutic and curative anti-HIV and anti-apoptotic effects. The Chelidonium majus, greater celandine, is a well known herb, containing alkaloids, like chelidonine, chelerythrine, sanguinarine, protopine and also malic acid, citric acid, various salts and natural resins. The whole plant or the roots can be used as drug.
10 The alcoholic tincture or aqueous extract prepared from the plant is utilized as therapeutic agent for a long time.
It was successfully utilized in human therapy against some liver and bile disease and also against goat. It proved to be useful in veterinary medicine against distension and against some other ailments. Details of the
15 above mentioned effects are discussed in the book entitled "Therapeutic effects of herbs" pp. 134-135, written by Aladar Bela Varrό (Kaposvar, 1991). It is also known that the thiophosphoric acid derivatives of the alkaloids isolated from Chelidonium majus exert antitumor effect.
These facts are detailed in the following articles: Drugs Exptl. Clin.
20 Res. XVIII (Suppl.) 17-20 (1992) and Pol. J. Pharmacol. Pharm. 44, 227-239 (1992).
In our experimental work it was found that both the alcoholic and aqueous-alcoholic extract of Chelidonium majus has potent anti-HIV activity, suφrisingly, this interesting effect of the extracts was not known before.
25 It was shown in our laboratory that the extract of the Chelidonium majus synergistically potentiate the activity of some therapeutically utilized antiviral compounds and the alkaloids of the herb, including chelidonine, chelerythrine and sanguinarine, also exerted potent anti-HIV activity.
Similarly, the extract of the Chelidonium majus enriched with the above mentioned alkaloids shows potent anti-HIV activity.
It was also observed in our laboratory that the above products not only potent anti-HIV agents but also affects the apoptosis (cell death), decreasing it.
Consequently, the subject of the invention are medicinal plant based preparation and its compounds with therapeutic and curative anti-HIV and anti-apoptotic effects.
The preparations of this invention are characterized is by the followings: an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and any other compounds with known anti-HIV activity, preferably 2'-deoxy-3'-azidothimidine, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonine and/or chelerythrine and/or- sanguinarine or a mixture of these compounds with 2'-deoxy- -3'-azidothimidine- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2'-deoxy- -3'-azidothimidine, and further supplemented - in given case with known medicinal auxiliary- and additive materials . The above mentioned effects of the preparations, made according to this invention, were not known up to the present.
The extract is prepared from the whole plant, or expediently from roots. The diluted solution, which is formed on extraction, is evaporated, or if required in some cases, lyophilized. The chelidonin, chelerythrine and sanguinarine may be isolated from the extract with preparative HPLC. The effects of the products and compounds prepared according to the invention, and the mode of the preparation are shown in the following examples.
Example 1
The dirt was removed from freshly picked roots of Chelidonium majus by washing and then dried partially at room temperature for 1-2 hours. The roots were cut up to small pieces and 100 part (mass) cut root was mixed with 250 part (mass) of 96% alcohol. The mixture was kept at room temperature in dark for 9 days and mixed up twice daily. The solid was separated from the liquid, Extract I, containing 1,5% (w/w) dry material. This product was partially evaporated at 45°C in vacuum, then the residue was mixed with two parts (mass) of alcohol. The mixture was filtrated. The filtrate contains 6,2% (w/w) dry material,Extract II.
Example 2
The procedure was completed according to the Example N°. 1 but instead of the roots of Chelidonium majus the whole plant was utilized. The dry material content of Extract I was 1,89% (w/w), the Extract II contained 6,5% by weight of dry material.
Example 3
To study the anti-HIV effect of the drugs stock solutions were prepared, as follows. Extract 1 and Extract II was evaporated in vacuum and the dry residue dissolved in DMSO in a final concentration of 100 mg/ml. These stock solutions were diluted with RPMI to get a final drug concentration of 100 μg/ml, and used in the treatment of infected cells. H9 cells were infected with HIV, and used in this study.
The drug solutions were added to the tissue culture (10^ cells/ml) at 1 or 6 hours prior infection, at the viral infection (0 time), 24 and 48 hours after infection.
The final drug concentration was 10 μg/ml at each addition. The viruses were HIV-1 IIIB, produced by H9 cells (2xl05 IU/ml). The infection was completed in 2 hours at 37 °C, in CO2 incubator. When the infection of the cells was finished the cells were washed thoroughly with PBS the 0,5 million cells were seeded into 24-well plates and 2 ml medium was added into each well. The culturing was performed in CO2 incubator. The infected cell cultures were treated with Extract I and Extract II as mentioned above, appropriate control tissue cultures were also run, without drug.
The results were as follows.
In both cases (the first treatment at -6 hour and at -1 hour) the viral replication was inhibited by the Extract I until the 5th day. On the 5th day, 30% inhibition was observed in the viral -infected cultures where the first treatment was at -1 hour and 90% inhibition was observed in the viral- infected cultures where the first treatment was at -6 hour. The Extract II inhibited the virus replication 45%, when the first treatment was performed at -1 hour, and showed 90% inhibition when the first treatment was 6 hours before infection.
Example 4
In this experiment MT4 cells were infected with HIV. The Extract I was added to the tissue cultures 4 hours prior infection, 24 and 48 hours after viral infection. In Experiment A the final concentration of the extract (dry material) was 1 μg/ml. In Experiment B the final concentration of the extract (dry material) was 3 μg/ml. Control cultures were also prepared without drug. The virus concentrations were measured on the 5th day by determining the reverse transcriptase activity of the cell free medium. In Experiment A the amount of virus was 20,2%, in Experiment B the amount of virus was 4,4% ot fhe controls.
Example 5
This example is similar to the N°. 4, but in Experiment A: the extract is replaced with 1 μg/ml AZT; in Experiment B: 1 μl/ml AZT 1 μg/ml dry- material of extract II is combined. In both cases, the active compound and mixture is given to the tissue culture only once, after the viral infection. The concentration of produced virions were determined on the 13th day of postinfection measuring the activity of reverse transcriptase in the cell free medium. In Experiment A the reverse transcriptase activity was 19,9% compared to the control, in Experiment B this value was only 1,4%, representing 98,6% inhibition.
Example 6
MT4 cells were infected with HIV-1 IIIB and the virus replication was inhibited using the following agents: chelidonine (I), chelerythrine (III), sanguinarine (II). The inhibition of virus replication was followed by
determining the reverse transcriptase activity as above, on 5th and 8th day after viral infections.
The control values (without drugs) were on 5th day: 153 824 cpm on 8th day: 56 266 cpm.
The results are summarized in the following table.
The results, summarized in the above table, clearly indicate that the compounds No I. II and III. are active as single agents at a concentration as low as 1 μg/ml, exerting potent anti-HIV activity compared to the controls.
Claims
1. Medicinal plant extract preparation and its compounds based on medical plant with therapeutic and curative anti-HIV and anti-apoptotic effects characterized by that the preparation is an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9% by weight of dry material, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and any other compounds with known anti-HIV activity, preferably 2'-deoxy-3'azidothimidine, or- chelidonoine and/or chelerythrine and/or sanguinarine or a mixture of these compounds with 2'-deoxy-3'-azidothimidine, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9% by weight of dry material and chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2'-deoxy-3'- azidothimidine, or- the above preparations and/or compounds further supplemented with known medicinal auxiliary- and additive materials.
2. Preparation according to the Claim 1. characterized by that it is an alcoholic extract of the root of Chelidonium majus containing 1-10% by weight of dry material.
3. Preparation according to the Claim 1. characterized by that it is a mixture of the alcoholic extract of the root of Chelidonium majus containing 1-10%) by weight of dry material and 2'-deoxy-3'-azidothymidine.
4. Preparation according Claim 1. characterized by that it contains chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2'-deoxy-3'-azidothimidine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU25195/97A AU2519597A (en) | 1996-04-26 | 1997-04-16 | Anti-hiv activity of medical plant extract preparation and its compounds with therapeutic and curative effect |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP9601096 | 1996-04-26 | ||
| HU9601096A HUP9601096A2 (en) | 1996-04-26 | 1996-04-26 | Pharmaceutical and medicine composition of anti-hiv activity based on medicinal plants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997040844A2 true WO1997040844A2 (en) | 1997-11-06 |
| WO1997040844A3 WO1997040844A3 (en) | 1998-01-08 |
Family
ID=89993918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU1997/000015 WO1997040844A2 (en) | 1996-04-26 | 1997-04-16 | Anti-hiv activity of medicinal plant extract preparation |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2519597A (en) |
| HU (1) | HUP9601096A2 (en) |
| WO (1) | WO1997040844A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025365A (en) * | 1997-03-25 | 2000-02-15 | Arch Development Corp. | Chelerythrine and radiation combined tumor therapy |
| CN111518158A (en) * | 2020-06-16 | 2020-08-11 | 北京赫尔默技术有限公司 | Compound for resisting hand-foot-and-mouth disease and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3128018A1 (en) * | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "METHOD FOR DIAGNOSTICING AND FOR THE THERAPEUTIC TREATMENT OF TUMORS AND / OR INFECTIOUS DISEASES OF DIFFERENT TYPES WITH PREPARATIVE USE OF ALKALOID COMPOUNDS OR THEIR SALTS" |
| CH660456A5 (en) * | 1984-02-02 | 1987-04-30 | Bupharm Ag | Therapeutic agent for combating of by herpesvirus infections caused. |
| EP0210815A3 (en) * | 1985-07-25 | 1988-04-20 | Beecham Group Plc | 6-beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use |
-
1996
- 1996-04-26 HU HU9601096A patent/HUP9601096A2/en unknown
-
1997
- 1997-04-16 WO PCT/HU1997/000015 patent/WO1997040844A2/en active Application Filing
- 1997-04-16 AU AU25195/97A patent/AU2519597A/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025365A (en) * | 1997-03-25 | 2000-02-15 | Arch Development Corp. | Chelerythrine and radiation combined tumor therapy |
| CN111518158A (en) * | 2020-06-16 | 2020-08-11 | 北京赫尔默技术有限公司 | Compound for resisting hand-foot-and-mouth disease and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| HU9601096D0 (en) | 1996-06-28 |
| WO1997040844A3 (en) | 1998-01-08 |
| AU2519597A (en) | 1997-11-19 |
| HUP9601096A2 (en) | 1998-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaplan et al. | Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis | |
| US8366935B2 (en) | Phyllanthus extract | |
| RU2518738C2 (en) | Compositions for treating upper airways diseases and influenza symptom complex | |
| CA2066155A1 (en) | Antiviral agent for human immunodeficiency virus | |
| Palomino et al. | Screening of South American plants against human immunodeficiency virus: preliminary fractionation of aqueous extract from Baccharis trinervis | |
| CA2009505C (en) | Inhibitor of herpesvirus adsorption | |
| WO2017013568A1 (en) | Anti-herpes composition and anti-herpes pharmaceutical formulation | |
| EP0199429B1 (en) | Manufacture of a medicament for treating viral hepatitis | |
| WO1997040844A2 (en) | Anti-hiv activity of medicinal plant extract preparation | |
| KR20000069296A (en) | Extracts of Salvia Species Having Antiviral Activity | |
| US6156349A (en) | Method of treating HIV infection with suppository containing mammalian liver extract | |
| CN110269854A (en) | The new medical use of sanggenon C | |
| RU2182828C1 (en) | Composition showing anti-hiv and anti-herpes activity | |
| WO1990003172A2 (en) | Bile acids for treatment of viral infections | |
| DE69610045T2 (en) | Use of a raw plant extract for the manufacture of a medicament for the treatment of HIV infections | |
| JP3002700B2 (en) | Anti-AIDS virus agent | |
| KR100668689B1 (en) | Antiviral Composition Against Rhinoviruses | |
| RU2244554C1 (en) | Agent for treatment of viral hepatitis c | |
| US5283239A (en) | Inhibitor of herpesvirus absorption | |
| ES2761429T3 (en) | Antiviral pharmaceutical composition, containing an extract of Juncus acutus | |
| JPS6137731A (en) | Remedy for diabetes for oral administration containing guava leaf extract as active component | |
| RU1805967C (en) | Biologically active substance used against aids virus | |
| JP2002510640A (en) | Herbal composition for prevention and treatment of AIDS | |
| CN110279752B (en) | Fast-growing eucalyptus leaf extract and its preparation method and anti-HIV application | |
| JPH0474333B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97538679 Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |